2 completed, 1 terminated. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Terminated 1 |
Follow Flucloxacillin: new trials by email Literature Review of Flucloxacillin trials Research Report on Flucloxacillin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA Dalbavancin, Vancomycin, Oxacillin - Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections | Phase 3 | Completed | AbbVie | 199 | 2017-03-30 | 2024-09-19 |
| Combination Antibiotic Therapy for Methicillin Resistant Staphylococcus Aureus Infection Beta-Lactam - Methicillin-Resistant Staphylococcus Aureus | Phase 3 | Terminated | Menzies School of Health Research | 358 | 2015-08-26 | 2018-12-19 |
| Staphylococcus Aureus Bacteremia Antibiotic Treatment Options Trimethoprim-Sulfamethoxazole, Clindamycin, Linezolid - Staphylococcus Aureus Infection | Phase 3 | Completed | Heinrich-Heine University, Duesseldorf | 215 | 2013-12-01 | 2020-05-27 |
Bacterial Infections (1) · Sepsis (1) · Staphylococcal Infections (1) · Staphylococcal Skin Infections (1)
AbbVie (1) · Heinrich-Heine University, Duesseldorf (1) · Menzies School of Health Research (1)
Spain (2) · Argentina (1) · Australia (1) · Belarus (1) · Brazil (1) · Bulgaria (1) · Chile (1) · Colombia (1) · France (1) · Georgia (1) · Germany (1) · Greece (1) · Guatemala (1) · Israel (1) · Latvia (1)
Achim J Kaasch, MD (1) · Joshua Davis, MBBS, FRACP (1) · Steven Tong, MBBS, FRACP (1)
PMID 26452342, PMID 27029920, PMID 32044943, PMID 32051007, PMID 38244557
2014 (1)